Kiniksa Pharmaceuticals International (KNSA) EBITDA Margin (2021 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported EBITDA Margin for 6 consecutive years, with 11.16% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA Margin fell 169.0% year-over-year to 11.16%; the trailing twelve-month figure through Jun 2026 stood at 11.92% (up 1108.0% YoY), and the FY2025 full-year result was 11.4%, up 2217.0% from the prior year.
• EBITDA Margin fell to 11.16% in Q2 2026 per KNSA's latest filing, from 13.66% in the prior quarter.
• Across five years, EBITDA Margin topped out at 46.82% in Q3 2022 and bottomed at 72.44% in Q1 2022.
• Historically, EBITDA Margin has averaged 5.9% across 5 years, with a median of 0.01% in 2023.
• The sharpest annual moves came in 2022 and 2023: EBITDA Margin jumped 45461 bps in 2022, then tumbled 6312 bps in 2023.
• Over 5 years, EBITDA Margin stood at 9.77% in 2022, then slumped by 99 bps to 0.1% in 2023, then sank by 16315 bps to 15.75% in 2024, then soared by 162 bps to 9.78% in 2025, then advanced by 14 bps to 11.16% in 2026.
• According to Business Quant data, EBITDA Margin over the past three periods registered 11.16%, 13.66%, and 9.78% for Q2 2026, Q1 2026, and Q4 2025 respectively.